Company Overview

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. Founded by Robert D. Walter in 1979, the company is headquartered in Dublin, OH. It plays a critical role in the healthcare supply chain, providing essential products and services to a wide range of healthcare providers.

Business Segments and Operations

The company operates through two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. It offers customized solutions to hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients receiving care at home.

Pharmaceutical and Specialty Solutions

Cardinal Health is one of the three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $200 billion in annual US drug distribution sales (fiscal 2025), the company supplies approximately one-fourth of the overall market. Cardinal Health, alongside Cencora and McKesson, collectively hold well over 90% of the US pharmaceutical wholesale industry.

This segment:

- Distributes branded and generic pharmaceutical products, specialty pharmaceuticals, over-the-counter healthcare and consumer products, and medical supplies.

- Provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products.

- Operates as the second largest pharmaceutical distributor in the United States and the largest nuclear pharmacy.

Global Medical Products and Distribution

Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities across North America, Europe, and Asia. This segment encompasses:

- Manufacturing, sourcing, and distributing Cardinal Health branded medical, surgical, and laboratory products and devices, including items such as exam and surgical gloves; needles, syringes, and sharps disposals; compression solutions; incontinence products; nutritional delivery items; and wound care products.

- Distribution of a wide range of national brand products, including medical, surgical, and laboratory items.

- Manufacturing, preparing, delivering, and distributing radiopharmaceuticals and related treatments.

Financial Performance

Fiscal Year 2025 Results

For fiscal year 2025, Cardinal Health reported:

- Revenue: $222.58 billion (a decrease of -1.87% compared to the previous year's $226.83 billion).

- Earnings: $1.56 billion (an increase of 83.22%).

Market Capitalization and Valuation

- Market Capitalization: $36 billion (as of September 20, 2025).

- Price-to-Earnings (P/E) Ratio: 23.19 (as of September 20, 2025).

- The market capitalization places CAH in the large capitalization category.

Dividend Information

Cardinal Health (CAH) pays dividends to its shareholders. As of September 20, 2025:

- Dividend Rate: $2.0275 annually.

- Dividend Yield: 1.37%.

The Board of Directors approved a quarterly dividend of $0.5107 per share.

Recent Strategic Developments

Solaris Health Acquisition

The company is set to acquire Solaris Health, a urology management services organization (MSO), for approximately $1.9 billion in cash. This acquisition, through Cardinal Health's multi-specialty MSO, The Specialty Alliance, aims to expand its capabilities in specialized healthcare services.

Facility Expansion

Cardinal Health continues to expand its operational footprint with strategic investments in logistics and distribution:

- In September 2025, Cardinal Health unveiled its newly operational Consumer Health Logistics Center, a significant 350,000-square-foot facility located in Groveport, Ohio.

- The company opened a new distribution center in Fort Worth, Texas, specifically designed to support at-home healthcare solutions.

Strategic Initiatives

Cardinal Health launched the Cardinal Health™ One Voice Initiative. This program provides financial support to state pharmacy associations, empowering them to enhance advocacy efforts for independent pharmacists.

Market Position and Competition

Cardinal Health holds a strong position in pharmaceutical distribution, serving nearly one-third of the industry. This scale provides substantial negotiation leverage with generic drug manufacturers. The company's primary competitors in the pharmaceutical distribution sector are Cencora and McKesson.

However, reimbursement pressures on pharmacy and provider customers have led to an increased emphasis on cost containment, which in turn, puts pressure on Cardinal Health's profitability.

Risk Factors

Cardinal Health (CAH) has a beta rating of 0.68, indicating that its stock is less volatile than the overall market on average. The company faces various operational challenges, including ongoing pricing pressures within the pharmaceutical distribution sector and intense competitive market dynamics across both of its business segments.

Cardinal Health remains a significant and integral player in the healthcare supply chain. It leverages its extensive scale and established market position to serve healthcare providers across multiple geographies, while continuously adapting to evolving industry trends and stringent regulatory requirements.